Organization | German Center for Cardiovascular Research e. V. (DZHK)

German Center for Cardiovascular Research e. V. (DZHK) Report issue

Government Phase 2 Phase 3 Phase 4

Founded: Berlin Germany (2012)

Organization Overview

First Clinical Trial

2017

NCT03312855

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)

Active Ingredients

Drugs in Phase 4 Trials (10)

acetylsalicylic acid (aspirin) (1 trial)

apixaban (eliquis) (1 trial)

bisoprolol (zebeta) (1 trial)

clopidogrel (plavix) (1 trial)

dabigatran (pradaxa) (1 trial)

diltiazem (cardizem) (1 trial)

edoxaban (savaysa) (1 trial)

phenprocoumon (liquamar) (1 trial)

rivaroxaban (xarelto) (2 trials)

warfarin (coumadin) (1 trial)

Drugs in Phase 3 Trials (3)

mycophenolate (CellCept) (1 trial)

prednisolone (hydeltra) (1 trial)

spironolactone (aldactone) (1 trial)

Drugs in Phase 2 Trials (1)

revacept (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Atrial Fibrillation (Phase 4)

Coronary Artery Disease (Phase 2)

Coronary Disease (Phase 2)

Myocardial Ischemia (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial APIs: 14